caplacizumab

FDA Drug Profile — Cablivi

Drug Details

Generic Name
caplacizumab
Brand Names
Cablivi
Application Number
BLA761112
Sponsor
Genzyme Corporation
NDC Codes
2
Dosage Forms
KIT, INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Routes
N/A
Active Ingredients
CAPLACIZUMAB

Indications and Usage

1 INDICATIONS AND USAGE CABLIVI is indicated for the treatment of adult and pediatric patients 12 years of age and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy. CABLIVI is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult and pediatric patients 12 years of age and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy. ( 1 )